Renexxion Ireland is a leading gastrointestinal (GI) biopharmaceutical company focused on developing innovative therapeutic agents. Their flagship product, Naronapride (ATI-7505), is a potential best-in-class prokinetic agent that addresses GI motility disorders such as gastroesophageal reflux disease (GERD), gastroparesis, chronic idiopathic constipation (CIC), and irritable bowel syndrome (IBS-c). With over 974 subjects treated in clinical trials, including four Phase-2 trials, Naronapride has shown efficacy in both lower and upper GI indications.

It has also undergone a thorough QT study to confirm its cardiac safety profile. Currently, Naronapride is in Phase 2+/3 development. Renexxion Ireland has entered into a Licensing and Collaboration Agreement with Dr.

Falk Pharma GmbH, expanding its reach for naronapride in Greater Europe, Russia, Central Asian Republics, and parts of Australasia. In the US, Renexxion is prioritizing PPI non-responsive GERD, a condition affecting up to 40% of GERD patients who do not respond to existing proton pump inhibitors (PPIs). Renexxion's vision is to become a global leader in GI biopharmaceuticals, actively pursuing ongoing research and potential partnerships in Greater China and Japan.

With a commitment to improving outcomes and patients' quality of life, Renexxion is dedicated to addressing the unmet needs in GI healthcare